PDS Biotechnology Corp Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)1.37 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $0.71Price as of 1 Oct 2026 Data confidenceNot applicable Market Cap $51.2M Shares Outstanding 72.5M diluted Next Earnings Date12 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary PDS Biotechnology is a clinical-stage immunotherapy company leveraging its proprietary Versamune platform to target HPV-associated cancers. The investment thesis centers on the potential of its lead candidate, PDS0101, which has demonstrated a median overall survival of 39.3 months in Phase 2 trials for head and neck cancer, significantly outperforming standard-of-care benchmarks. Recent protocol amendments to the Phase 3 VERSATILE-003 trial incorporate progression-free survival (PFS) as an interim primary endpoint, establishing a potential accelerated approval pathway. While the company remains pre-revenue and faces near-term balance sheet risks, its recent debt refinancing and the establishment of a $50 million ATM facility provide the necessary financial flexibility to reach key clinical readouts. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$4.50 Mean target$5.75 High · most bullish analyst$7.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario The company experiences clinical delays or safety concerns in the VERSATILE-003 trial, or the interim PFS data fails to meet the threshold for accelerated approval. Slower-than-expected enrollment extends the cash burn, forcing highly dilutive equity raises at depressed share prices. The company fails to regain compliance with Nasdaq's minimum bid price, leading to delisting to the OTC market. Base CaseCentral scenario The company successfully restarts and advances enrollment in the Phase 3 VERSATILE-003 trial. Efficacy data from the Phase 2 trial of PDS0101 in combination with pembrolizumab remains strong, and preliminary readouts for PDS01ADC in colorectal and prostate cancers are positive. The company manages its cash burn effectively, utilizing its ATM facility to maintain a sufficient runway without excessive dilution, and regains compliance with Nasdaq's minimum bid price rule. Bull CaseUpside scenario The Phase 3 VERSATILE-003 trial meets its interim PFS endpoint, paving the way for accelerated FDA approval of PDS0101 in combination with pembrolizumab. The triple combination therapy (PDS0101 + PDS01ADC + pembrolizumab) shows outstanding efficacy in early readouts, attracting a major pharmaceutical partner and securing non-dilutive funding that extends the cash runway indefinitely. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |